Table 2.
Outcome | N (%) events | Event rates | Crude HR (95%CI) | p value | Adj. HR (95%CI)a | p value |
---|---|---|---|---|---|---|
Primary outcome | ||||||
EF < 40% | 1344 (22.9) | 19.2 (18.2–20.2) | Ref. | <.001 | Ref. | <.001 |
EF = 40% | 100 (13.3) | 10.3 (8.5–12.5) | 0.55 (0.44‐0.67) | 0.65 (0.53‐0.81) | ||
CV death | ||||||
EF < 40% | 833 (14.2) | 10.9 (10.2‐11.7) | Ref. | <.001 | Ref. | <.001 |
EF = 40% | 52 (6.9) | 5.0 (3.8‐6.6) | 0.47 (0.35‐0.62) | 0.58 (0.43‐0.77) | ||
All‐cause death | ||||||
EF < 40% | 959 (16.4) | 12.6 (11.8–13.4) | Ref. | <.001 | Ref. | .001 |
EF = 40% | 68 (9.0) | 6.6 (5.2–8.4) | 0.53 (0.41‐0.68) | 0.65 (0.50–0.83) | ||
HF hospitalization | ||||||
EF < 40% | 787 (13.4) | 11.2 (10.5‐12.0) | Ref. | <.001 | Ref. | .008 |
EF = 40% | 64 (8.5) | 6.6 (5.2–8.4) | 0.60 (0.46‐0.77) | 0.70 (0.53‐0.91) |
Note: The primary outcome is a composite of cardiovascular death or cardiovascular hospitalization. Median follow‐up time to death or censor = 1.3 (1.0‐1.7) years. Event rates per 100 person‐years.
Abbreviations: CV, cardiovascular; EF, left ventricular ejection fraction; HF, heart failure.
Model adjusted on age, sex, body mass index, heart rate, estimated glomerular filtration rate, sodium, potassium, previous myocardial infarction, peripheral vascular disease, previous heart failure hospitalization, atrial fibrillation, diabetes, hypertension, chronic obstructive pulmonary disease, angiotensin‐converting‐enzyme‐inhibitors/angiotensin‐receptor blockers, beta‐blockers, Q‐wave myocardial infarction, Killip class, reperfusion therapy, and study drug (eplerenone or placebo).